Brief: Nicox FY Net Revenue Up At 8.9 Million Euros

Nicox SA

20/01/2021 06:40

Jan 20 (Reuters) - Nicox SA  NCOX.PA :
    * NICOX PROVIDES FOURTH QUARTER 2020 BUSINESS UPDATE AND
FINANCIAL
HIGHLIGHTS
    * INITIATED TWO LARGE CLINICAL TRIALS: DENALI, SECOND PHASE
3 OF
NCX 470 IN GLAUCOMA, AND MISSISSIPPI, A PHASE 2B OF NCX 4251 IN
BLEPHARITIS
    * CASH OF EUR 47.8 MILLION AT DECEMBER 31, 2020
    * Q4 2020 NET REVENUE OF €5.8 MILLION, FULL YEAR 2020 NET
REVENUE
OF €8.9 MILLION AND CASH OF €47.8 MILLION AT DECEMBER 31, 2020
    * WE EXPECT TO ENTER INTO ADDITIONAL AGREEMENTS FOR
ZERVIATETM
(CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, FURTHER ENLARGING
LICENSED TERRITORIES AND INCREASING POTENTIAL FUTURE REVENUE
    * U.S. PRESCRIPTIONS FOR VYZULTA (®)IN Q4 2020 INCREASED BY
29%
OVER Q4 2019, AND FOR ZERVIATE (TM)BY 56% OVER Q3 2020
    * AS OF DECEMBER 31, 2020,  HAD FINANCIAL DEBT OF €18.4
MILLION IN
THE FORM OF A BOND FINANCING AGREEMENT WITH KREOS CAPITAL  AND A
€2 MILLION CREDIT AGREEMENT WITH SOCIÉTÉ GÉNÉRALE AND LCL
    * NCX 470 FIRST PHASE 3 TRIAL, MONT BLANC: TOP-LINE RESULTS
ARE
NOW PRUDENTLY EXPECTED IN H1 2022, INSTEAD OF Q4 2021, GIVEN
PROBABLE DELAYS IN RECRUITMENT DUE TO COVID-19
    * NCX 4251 PHASE 2B TRIAL, MISSISSIPPI: TOP-LINE RESULTS ARE
CURRENTLY EXPECTED IN Q4 2021

Source text for Eikon:  ID:nGNE862qLl 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))